AI Drug Repurposing Market Report 2026-2033: $7.7B Outlook

Ai Drug Repurposing Market Report: Valuation and Forecast Timeline

Our proprietary primary research places the global artificial intelligence in drug repurposing market at USD 1.3 billion in 2025, rising to USD 1.7 billion in 2026 and expanding to USD 7.7 billion by 2033 at a 24.5% CAGR. North America captured a 52.9% revenue share in 2025, while Asia Pacific is the fastest-growing region through 2033.

• 2025 baseline: USD 1.3 billion, anchored by 66.6% software and platform revenue.
• 2026 near-term estimate: USD 1.7 billion as enterprise contracts scale.
• 2033 forecast: USD 7.7 billion, a roughly six-fold expansion from 2025.
• Growth vector: Redirection of R&D budgets from de novo discovery toward validated repurposing pipelines.

This Ai Drug Repurposing Market Report is built from 70%+ primary interviews across platform vendors, biotech sponsors, and CROs, not aggregated secondary estimates.

Cost Economics of De Novo Drug Development

The central commercial engine for AI repurposing is the USD 2 billion-plus cost of traditional de novo development and the decade-plus timeline it demands. Repurposing skips early-stage safety work, and AI compresses biological, chemical, and clinical data analysis into weeks.

• Reductions in trial financial loss potential of USD 800 million to USD 1.4 billion per failed program make repurposing attractive even at lower peak-sales assumptions.
• Pharmaceutical and biotechnology companies held a 59.2% end-use share in 2025, reflecting this economics-driven adoption.

Machine Learning and Deep Learning Technology Stack

Machine learning and deep learning led the technology segment with a 45.8% revenue share in 2025. Multi-omics integration (genomics, proteomics, metabolomics) with biomedical literature and real-world patient records underpins novel drug-target association discovery.

• Software and platform revenue reached 66.6% of the component mix in 2025; cloud-based deployments accounted for 55% of platform revenue on our survey basis.
• A notable share of platform economics is shifting toward recurring subscription and milestone-linked deal structures, reducing upfront capital constraints for small biotech buyers.

Oncology, Rare Disease, and Target Identification Applications

Oncology led applications with a 36.7% share in 2025, driven by high unmet need, premium pricing, and biomarker-rich datasets. Target identification and validation represents roughly 32% of application revenue, ahead of molecule screening.

• Rare and orphan diseases: Approximately 300 million people live with rare diseases globally, affecting 3.5%–5.9% of the population; about 80% are genetically caused, with nearly 70% presenting in childhood. AI enables analysis of small, fragmented cohorts that traditional trials cannot economically address.
• Infectious disease and CNS/neurology are the next frontiers: clinical validation costs are lower and real-world evidence volumes are high.
• Large-population regional cohorts include an estimated 49–82 million affected individuals in China and 25–36 million in the EU, creating addressable data pools for cohort-based repurposing models.

Clinical Validation Milestones and Platform Partnerships

Validation momentum is no longer theoretical. Named clinical and partnership milestones set 2020–2025 apart from the prior research-only era.

• April 2025: Plex Research partnered with Ginkgo Bioworks to apply AI to the GDPx2 transcriptomics dataset for compound-induced gene expression, targeting novel disease mechanisms.
• July 2025: Healx expanded partnership activity to industrialize rare-disease repurposing pipelines.
• Partnership intensity is rated high in our primary survey, alongside a high degree of innovation and high regulatory impact; regional expansion remains moderate.

North America, Europe, and Asia Pacific Regional Dynamics

• The U.S. remains the single largest country market, supported by the largest concentration of AI-native biotech sponsors.
• Policy tailwinds include expanded FDA stakeholder engagement on supplemental indications for existing drugs.
• In Asia Pacific, healthcare database expansion and warehouse-scale biomedical data infrastructure are the primary adoption enablers.

Funding, Collaboration, and Capital Formation Signals

Capital is flowing into repurposing-specific vehicles rather than generic AI drug discovery, signaling market maturation.

• February 2024: ARPA-H awarded Every Cure a USD 48.3 million, three-year contract, a major public commitment to repurposing.
• July 2024: Formation Bio raised USD 372 million in Series D funding as an AI-native pharma business.
• M&A activity is moderate but rising, driven by technology capability acquisition and consolidation in a fragmented vendor field.
• Emerging players continue to enter, keeping the market slightly fragmented despite high innovation intensity.
• Public health need is quantifiable: the WHO estimated 1.495 billion people required interventions for neglected tropical diseases in 2023, a long-tail demand pool for repurposed anti-infectives.

Competitive Landscape and Commercial Positioning

Commercial leadership spans large-cap pharma portfolios, specialized AI platform vendors, and non-profit consortia. Large pharmaceutical firms use portfolio breadth and clinical data depth; specialists compete on model performance and data partnerships.

• Leading incumbents analyzed: Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Bristol-Myers Squibb Company, Astellas Pharma Inc., Abbott Laboratories.
• Specialist innovators: Biovista, Inc., NuMedii, Inc., BenevolentAI, Insilico Medicine, Atomwise, Every Cure, DeepDrug, Plex Research, Healx, Formation Bio.
• The commercial battleground is shifting from model accuracy to validated hit rate and regulatory-grade evidence generation; vendors that cannot demonstrate clinical translation will face pricing pressure.
• Cloud-based platforms (55% of deployment in 2025) are the preferred delivery model due to scalability and lower infrastructure overhead for mid-sized biotech buyers.